ArticleHead & face medicine2010
Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients.
Article in Head & face medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.Clinical oral investigations · 2014Trial
- Postoperative healing and recurrence in osteonecrosis of the jaw: influence of risk factors and surgical approach.Clinical oral investigations · 2026Article
- The effects of geranylgeranyl diphosphate synthase inhibitor treatment on osteoblast biology and application in a conditioned media model of myeloma bone disease.Bone reports · 2025Article
- Preoperative Assessment of Medication-Related Osteonecrosis of the Jaw Using [18F]fluoride Positron Emission Tomography (PET)/CT and [18F]fluorodeoxyglucose PET/MRI in Correlation with Histomorphometry and Micro-CT-A Prospective Comparative Study.Diagnostics (Basel, Switzerland) · 2024Article
- Oral health conditions in patients under antiresorptive therapy are comparable to unexposed during supportive periodontal care.Clinical oral investigations · 2023Article
- Risk Factors for Bisphosphonate-Related Osteonecrosis of the Jaws in Bone Metastatic Breast and Prostate Cancer under Zoledronate Treatment: A Retrospective Analysis from 10 Years of Evaluation.Asian Pacific journal of cancer prevention : APJCP · 2023Observational
- The association between the severity of periodontitis and osteonecrosis of the jaw in patients with different cancer locations: a nationwide population-based study.Clinical oral investigations · 2022Article
- A Retrospective Data Analysis for the Risk Evaluation of the Development of Drug-Associated Jaw Necrosis through Dentoalveolar Interventions.International journal of environmental research and public health · 2022Article
- Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.Cancers · 2021Review
- Determination of bisphosphonates anti-resorptive properties based on three forms of ceramic materials: Sorption and release process evaluation.Journal of pharmaceutical analysis · 2021Article
- Positive impact of Platelet-rich plasma and Platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid.Scientific reports · 2019Article
- Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat.Clinical oral investigations · 2018Article
- Bone-targeted agents in multiple myeloma.Hematology reports · 2018Article
- Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.Journal of translational medicine · 2017Article
- The Prevention of Medication-related Osteonecrosis of the Jaw.Deutsches Arzteblatt international · 2017Article
- Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.Dentistry journal · 2016Review
- Dental implants in patients treated with antiresorptive medication - a systematic literature review.International journal of implant dentistry · 2016Review
- Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw.Dentistry journal · 2016Review
- Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma.Dentistry journal · 2016Review
- Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ).Dentistry journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates.
methodsIn two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000--Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006--Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalence. PubMed search terms were: bisphosphonat, diphosphonate, osteonecrosis, prevalence and incidence.
resultsIn the RS, data from 81 of 161 patients could be obtained; four patients (4.9%) developed BP-ONJ. In the CSS, 16 of 78 patients (20.5%) developed BP-ONJ. All patients with BP-ONJ had received zoledronate; 12 of these had had additional bisphosphonates. All except one had an additional trigger factor (tooth extraction [n = 14], dental surgical procedure [n = 2], sharp mylohyoid ridge [n = 3]).
conclusionThe prevalence of BP-ONJ may have been underestimated to date. The oral examination of all patients in this CSS might explain the higher prevalence, since even early asymptomatic stages of BP-ONJ and previously unnoticed symptomatic BP-ONJ were recorded. Since nearly all patients with BP-ONJ had an additional trigger factor, oral hygiene and dental care might help to reduce BP-ONJ incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.